Sorted By Test Name - Mayo Medical Laboratories

CA19
9288
CDG
89891
Carbohydrate Antigen 19-9 (CA 19-9), Serum
Clinical Information: Carbohydrate antigen 19-9 (CA 19-9) is a modified Lewis(a) blood group
antigen. CA 19-9 may be elevated in patients with gastrointestinal malignancies such as
cholangiocarcinoma, pancreatic cancer, or colon cancer.
Useful For: Potentially useful adjunct for diagnosis and monitoring of pancreatic cancer May be used
for differentiating patients with cholangiocarcinoma and primary sclerosing cholangitis (PSC) from those
with PSC alone
Interpretation: Serial monitoring of carbohydrate antigen 19-9 (CA 19-9) should begin prior to
therapy to verify post-therapy decreases in CA 19-9 and to establish a baseline for evaluating possible
recurrence. Single values of CA 19-9 are less informative. Elevated values may be caused by a variety of
malignant and nonmalignant conditions including cholangiocarcinoma, pancreatic cancer, and/or colon
cancer.
Reference Values:
1mo), and in liver disease, the Apo-CIII2 may be
increased. In children younger than 6 months and clinically suspected of having ATP6V0A2-CDG may
have normal transferrin profile with abnormal Apo-CIII profile. CDG typically present as multisystemic
disorders with a broad clinical spectrum including: developmental delay, hypotonia, with or without
neurological abnormalities, abnormal magnetic resonance imaging findings, skin manifestations, and
coagulopathy. There is considerable variation in the severity of this group of diseases, ranging from
hydrops fetalis to a mild presentation in adults. In some subtypes (Ib, in particular), intelligence is not
compromised. CDGs should be suspected in all patients with developmental delay, unexplained liver
dysfunction, abnormal subcutaneous fat distribution may or may not be present in all cases, stroke-like
episodes, unexplained hypoglycemia, liver disease, and with or without chronic diarrhea. The differential
diagnosis of abnormal transferrin patterns also includes liver disease not related to CDG including
uncontrolled galactosemia, hereditary fructose intolerance in acute crisis, and liver disease of unexplained
etiology. Transferrin and apolipoprotein CIII isoform analysis test is the initial screening test for CDG.
The results of the transferrin and apolipoprotein CIII isoform analysis should be correlated with the
clinical presentation to determine the most appropriate testing strategy including enzyme, molecular and
research based testing. If either CDG-Ia or CDG-Ib are suspected, it should be followed by enzymatic
analysis for phosphomannomutase and phosphomannose isomerase in leukocytes or fibroblasts
(PMMIL/PMMIF).
Useful For: Screening* test for congenital disorders of glycosylation *Positive test could be due to a
genetic or non-genetic condition. Additional confirmatory testing is required.
Interpretation: Results are reported as the mono-oligosaccharide/di-oligosaccharide transferrin ratio.
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 370